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Forskolin is a potent activator of adenylate cyclase in many tissues including the thyroid gland. We 
compared the effects of lo-’ M forskolin and 100 punits/ml TSH on the dynamics of T4 and T3 secretion 
from perfused dog thyroid lobes. Both agents induced pronounced increases in T4 and TJ secretion. The 
increase in secretion was significantly steeper during forskoiin than during TSH stimulation. This may 
suggest that early processes such as TSH-receptor interaction and the subsequent activation of the 
catalytic unit of adenylate cyclase are of importance for the pattern of very gradual increase in hormone 
secretion during TSH stimulation of the thyroid. In other respects forskolin seems to induce absolute and 
relative secretion of T3 and T4 very similar to those obtained by CAMP and TSH. 
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1, INTRODUCTION 
Forskolin is a potent activator of the adenylate 
cyelase in many tissues [ 1,2] including the thyroid 
gland [3-61. 
Here we have compared the effects of 10m5 M 
forskolin and 100 punits/ml TSH on the dynamics 
of T4 and T3 secretion from perfused dog thyroid 
lobes. One hundred punits/ml TSH induce a max- 
imal T4 and T3 secretion in our preparation [7] and 
10m5 M forskolin is known to induce rapid and 
profound activation of the thyroidal adenylate 
cyclase [3-61. This was done to evaluate the degree 
to which processes before CAMP are involved in 
the delayed and sluggish thyroid hormone response 
to TSH. To ascertain that forskolin actually ac- 
tivated the CAMP system in our model we 
measured CAMP in thyroid effluent. CAMP in ef- 
fluent is a good indicator of thyroidal CAMP [8,9]. 
2. MATERIALS AND METHODS 
Once-through thyroid perfusions were per- 
formed in four mongrel dogs weighing 20-27 kg. 
In each dog both of the two separate lobes were 
perfused simultaneously and independently using a 
buffer medium. The method has been described in 
[7]. Forskolin was infused in the left lobe in two 
experiments and in the right lobe in two ex- 
periments. The perfusion flow was 0.63 ml/min 
per lobe -0.5-I .O ml/min per g tissue. The perfu- 
sion pressure was constant in every perfusion and 
in the range 30-40 mm Hg. Forskolin or TSH 
were infused (13.5 pl/min) in the afferent catheters 
via a canula penetrating a rubber membrane giving 
the final concentrations indicated [lo], Forskolin 
was dissolved in ethanol, and diluted in perfusion 
medium. The final ethanol concentration in the 
medium during forskolin infusion was 0.2%. To 
the TSH containing medium was added a similar 
amount of ethanol. The tubes sampling 5 min ef- 
fluents contained EDTA to give a final concentra- 
tion of 40 mM., Samples were kept at - 20°C until 
analysis. 
T4 and T3 were measured by radioimmunoassays 
[11,12]; CAMP was measured as in [13]. In [9] it 
was demonstrated that CAMP was stable in the ef- 
fluent and that the total CAMP activity disap- 
peared after incubation with phosphodiesterase. 
The sensitivity of the CAMP assay was 0.4 nmol/l 
and inter- and intra-assay coefficients of variations 
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Fig. 1. CAMP in effluent from perfused dog thyroid 
lobes. One of the two lobes in a dog received 10m5 M
forskolin during the 60-90 min period of perfusion, 
while the other lobe received 100 punits/ml TSH during 
the same period. Mean + SE, n = 4. 
9.2 and 6.0010, respectively. TSH and forskolin did 
not interfere in any of the assays. 
Bovine TSH was from Ferring (Malmo, Sweden) 
and forskolin from Calbiochem (La Jolla, CA). 
Paired t-tests were employed for statistical 
evaluation using a 5% limit of statistical 
significance. 
3. RESULTS 
Fig.1 shows the effect of IO-’ M forskolin and 
100 ~units/ml TSH on the concentration of CAMP 
in effluent from perfused thyroid lobes. Both 
agents induced increases in CAMP which were high 
and nearly stable during the last 10 min of the 
30-min infusion period. Cessation of infusion of 
the stimulant was followed by a gradual decrease 
in cAMP release. The response to 10m5 M for- 
skolin was much higher than that to 100 /;tunits/ml 
TSH at all points. 
The increase in CAMP was accompanied after 
approximately 20 min by increases in Tq and T3 
secretion (fig.2). The initial phase of the hormone 
secretion was significantly steeper after stimulation 
with forskolin than after TSH. However, the 
response to forskolin began to decrease earlier 
after cessation of stimulation than that to TSH. 
During forskolin infusion, the initial increase in 
T3 secretion was slightly steeper than that in T4 
Tg nmol/l 
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Fig.2. T,+ and T3 in effluent from perfused thyroid lobes 
stimulated with lo-’ M forskolin or lOOpunits/ml TSH 
during the 60-90 min period. * p < 0.05, comparing 
values from the two lobes. Mean +- SE, n = 4. 
secretion. This is most easily depicted by the ratio 
T4/T3 in effluent showing a temporary fal1 during 
the early period of increase in secretion (fig.3). 
4. DISCUSSION 
Forskolin induced a considerable increase in 
CAMP which began already in the first 5-min sam- 
ple after the start of forskolin infusion. A con- 
siderably smaller increase in CAMP was seen dur- 
ing infusion of TSH. There was a lag period from 
the increase in CAMP until an increase was 
obtained in T4 and T3 secretion both during for- 
skolin and TSH infusion. However, the increase in 
hormone secretion was steeper after forskolin than 
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Fig.3. T~/TJ ratio in effluent from perfused thyroid 
lobes stimulated with lo-’ M forskolin during the 
60-90 min period. Average values from the 75-90 min 
period were significantly lower than average values from 
the 35-60 min period @ < 0.05). Mean f SE, n = 4. 
after TSH. This difference is not due to the more 
profound activation of the CAMP system by 
lo-’ M forskolin than by l~~u~ts/ml TSH. If 
higher doses of TSH which induce larger increases 
in CAMP [9], are employed the increase in T4 and 
T3 secretion becomes less steep than after 
100 +nits/ml 19,141. Hence 100 gunits/ml TSH 
induce the fastest rate of increase obtainable with 
TSH. 
This difference in effects may suggest hat the 
early processes involved in the TSH induced in- 
crease in thyroid hormone secretion such as 
TSH/receptor interaction and the subsequent ac- 
tivation of the cataiytic unit of the adenylate 
cyclase are relatively time-consuming, Forskolin 
activates CAMP generation more directly by in- 
teraction with the regulatory protein or the 
catalytic unit of the adenylate cyclase [3-61. Hence 
these early processes may be of significant impor- 
tance for the pattern of a slow increase in thyroid 
hormone secretion after TSH stimulation. Both 
TSH and forskoIin are administered via the 
vascular bed but still there might be differences in 
the diffusion time to reach the cells. Considering 
that even extremely high concentrations of TSH do 
not make the increase in hormone release more 
steep, such a difference in diffusion time is pro- 
bably of littIe importance. Another possibility is 
that TSH, besides activating the secretory pro- 
cesses, aIso activates a non-cAMP dependent 
mechanism which tends to give a slower and lower 
increase in hormone secretion. The presence of 
such a mechanism is suggested by our previous 
studies showing that the secretory response is 
dampened uring infusion of very high concentra- 
tions of TSH despite increasing CAMP formation 
[9,14]. Such a mechanism could be operative 
already at low TSH concentrations, albeit to a 
lesser degree. 
In [6], a study on the effects of forskolin on 
various intrathyroid~ processes known to be 
stimulated by TSH, it was concluded that forskolin 
could not be used to reproduce other intracellular 
effects of TSH than the activation of the CAMP 
system. The present study demonstrates that for- 
skolin, except for some minor differences, one of 
which is commented upon above, reproduces the 
effect of TSH on the process sequence leading to 
thyroid hormone secretion very closely. In this 
context, forskolin gave a similar temporary fall in 
the T4/T3 ratio in thyroid secretion as found 
previously when CAMP [Is] or TSH were used as 
stimulants [14,16]. 
The results are in accordance with the concept 
that most, but not necessarily all effects of TSH on 
thyroid hormone secretion in the dog [ 171 are 
mediated via the CAMP system. 
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